Type 2 Diabetes Mellitus Clinical Trial
Official title:
A Single Arm Feasibility Study of GlycoLeap, an On-line Lifestyle Modification and Self-management Program for People With Type 2 Diabetes
NCT number | NCT03091517 |
Other study ID # | GlycoLeap |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 22, 2017 |
Est. completion date | May 28, 2018 |
Verified date | July 2018 |
Source | Duke-NUS Graduate Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This single arm pilot study will explore the feasibility of GlycoLeap, a proprietary online lifestyle modification and self-management education program developed in Singapore for people with type 2 diabetes, as an add-on to primary care delivered through one of the SingHealth Polyclinics.
Status | Completed |
Enrollment | 100 |
Est. completion date | May 28, 2018 |
Est. primary completion date | May 19, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Age 21 - 70 years 2. Medical diagnosis of Type 2 diabetes in electronic health records or based on World Health Organisation diagnostic criteria 3. Last HbA1c result within 2 months of = 7.5% 4. BMI > 23 kg/m2 (if Asian) or BMI > 25 kg/m2 (if non-Asian) 5. Not on insulin 6. Owns a smartphone (iPhone or Android phone) and able to use it Exclusion Criteria: 1. Last HbA1c blood test older than 2 months 2. Cancer requiring treatment in past 5 years 3. Cardiovascular disease (heart attack or cardiac procedure within past 3 months) 4. Stroke or history/treatment for transient ischemic attacks in past 3 months 5. Chronic renal failure or dialysis 6. Amputation of lower limbs 7. Current use of medication for weight loss 8. Chronic treatment with systemic corticosteroids 9. History of bariatric surgery or extensive bowel resection 10. Unable to understand English |
Country | Name | City | State |
---|---|---|---|
Singapore | SingHealth Polyclinics - Tampines | Singapore |
Lead Sponsor | Collaborator |
---|---|
Duke-NUS Graduate Medical School | SingHealth Polyclinics |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in HbA1c levels (Effectiveness) | HbA1c or glycated haemoglobin is a measure of blood glucose levels. We will assess change in HbA1c levels. | Baseline, Month 6 | |
Secondary | Change in weight (Effectiveness) | We will assess change in weight | Baseline, Month 6 | |
Secondary | Proportion of individuals who are willing to participate (Reach) | Percentage of participants offered the GlycoLeap programme who agree to enrol | Baseline | |
Secondary | Extent of engagement in completing online health lessons (Implementation) | Number of online GlycoLeap health lessons completed | Throughout 6 month intervention duration | |
Secondary | Extent of engagement in submitting blood glucose logs (Implementation) | Number of blood glucose measurements logged per week in GlycoLeap's smartphone app | Throughout 6 month intervention duration | |
Secondary | Extent of engagement in submitting weight logs (Implementation) | Number of weight measurements logged per week in GlycoLeap's smartphone app | Throughout 6 month intervention duration | |
Secondary | Extent of engagement in submitting meal logs (Implementation) | Number of meals logged per week in GlycoLeap's smartphone app | Throughout 6 month intervention duration | |
Secondary | Extent of engagement with health coach (Implementation) | Number of messages sent to health coaches per week through GlycoLeap's smartphone app | Throughout 6 month intervention duration | |
Secondary | Change in HbA1c (primary outcome) as a function of program engagement (Effectiveness) | We will test whether those with greater engagement with the GlycoLeap program show greater improvements in HbA1c (primary outcome). | Baseline, Month 6, Throughout 6 month intervention duration | |
Secondary | Change in weight loss (secondary outcome) as a function of program engagement (Effectiveness) | We will test whether those with greater engagement with the GlycoLeap program show greater improvements in weight loss (secondary outcome). | Baseline, Month 6, Throughout 6 month intervention duration | |
Secondary | Degree of user satisfaction with the GlycoLeap program (Maintenance) | We will conduct a preliminary assessment of maintenance at the individual level via a user satisfaction survey at the month 6 follow-up. Participants will rate the smartphone app on a scale of 1 (Poor) to 5 (Excellent) and whether they would recommend the app to others for managing their diabetes on a scale of 1 (Would not recommend) to 5 (Would highly recommend). | Month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |